Printer Friendly

Interpharm Announces Delay in 10-K Filing.

HAUPPAUGE, N.Y. -- Interpharm Holdings, Inc. (Amex: IPA)("Holdings"), a manufacturer and distributor of generic pharmaceutical products, announced today that due to a delay in filing its Form 10-K, it received a notice from the American Stock Exchange Continued Listing Department that it is out of compliance with exchange rules.

In its Current Report on Form 8-K and Form 8-K/A filed with the SEC on October 12 and 15, 2007, respectively, Interpharm Holdings, Inc. ("Holdings") disclosed that as a result of negotiations with Wells Fargo Bank, National Association, acting through its Wells Fargo Business Credit operating division ("Wells Fargo"), Holdings would not be able to file its Form 10-K by its due date of October 15, 2007 and anticipates filing upon the conclusion of negotiations with Wells Fargo. Holdings further disclosed that on October 12, 2007, Holdings notified the American Stock Exchange ("AMEX") that it would not file its Form 10-K in a timely manner.

On October 15, 2007, Holdings received notice from the AMEX that trading in its common stock would be halted pending compliance with AMEX rules through the filing of financial information.

On October 16, 2007, Holdings received a notice from the AMEX Listing Qualification Department that it must file its Annual Report on Form 10-K as required by Sections 134 and 1101 of the AMEX Company Guide in order to maintain its AMEX listing. As previously disclosed, Holdings plans to file its Annual Report on Form 10-K at the conclusion of its negotiations with Wells Fargo.

About Interpharm Holdings, Inc.

Interpharm currently develops, manufactures and distributes generic prescription strength and over-the-counter pharmaceutical products. Interpharm will continue to focus on growing organically through internal product development and leveraging its strength in efficient and cost effective manufacturing. In addition, Interpharm will also continue to seek consummation of mutually beneficial strategic alliances and collaborations.


Statements made in this news release, contain forward-looking statements concerning Interpharm's business and products involving risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. The actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, development, shipment, market acceptance, and additional competition from existing and new competitors, changes in technology, and various other factors beyond Interpharm's control. Other risks inherent in Interpharm's business are set forth in its filings with the SEC, including, but not limited to, its Form 10-K, filed on September 28, 2006, its Form 10-Q filed on February 14, 2007 and Form 10-Q filed on May 15, 2007.

All information in this release is as of October 17, 2007. Interpharm undertakes no duty to update any forward-looking statements to conform the release to actual results or changes in its circumstances or expectations after the date of this release.
COPYRIGHT 2007 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2007, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Oct 17, 2007
Previous Article:Software Defined Radio Forum Launching Special Interest Group for International Tactical Radio Market.
Next Article:Web Crossing, Inc. Announces Exciting New Blog System for WebCrossing Neighbors 2.

Related Articles
PCB database viewing for SI analyses, Part 2: signal integrity modeling, simulation and measurements can demand frequent examination of the PCB...
USANA Health Sciences Inc. Regains Compliance with NASDAQ Listing Standards.
Neurogen Corporation Announces Appointment of Kenneth J. Sprenger to Vice President, Clinical Development and Operations.
Curis Announces Presentation at CHI's "Discovery on Target: Developing Inhibitors for Promising Drug Targets" Conference.
Santarus to Hold Third Quarter 2007 Financial Results Conference Call on November 1.
ImClone and Bristol-Myers Squibb Announce Joint Agreement with Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan.
Targacept Announces Plans to Develop Enantiomer of Mecamylamine as Augmentation Therapy for Depression.
BioSante Pharmaceuticals Common Stock Approved for Listing on NASDAQ Global Market.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters